Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.
CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.
Revalesio presents new RNS60 stroke data showing reduced brain tissue loss and shorter hospital stays. Discover what this could mean for stroke drug development.
Ananda Pharma launches Phase 2 ENDOCAN trial testing cannabidiol MRX1 for endometriosis pain. Explore what this study could change for women’s health.
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.
Theravance Biopharma halted its ampreloxetine program after a Phase 3 failure. Discover what the CYPRESS results mean for the company and the neurogenic hypotension market.
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Scinai Immunotherapeutics seeks €12M EU funding to advance PC111 for rare autoimmune skin diseases. Explore the clinical, regulatory, and industry implications.